This document discusses several factors relevant to strategic marketing:
1. It identifies key stakeholders for an NHS organization and a pharmaceutical company and their respective interests.
2. It outlines several strategic marketing frameworks and tools including Porter's competitive strategies wheel, product life cycle analysis, BCG matrix, GE/McKinsey matrix, and industry life cycle analysis.
3. It discusses blocks to creativity for individuals and organizations and examines Henry Ford's reluctance to change the Model T as an example.
4. It provides an overview of international market entry methods such as indirect exporting, direct exporting, licensing, joint ventures, and direct investment.
This document discusses several factors and concepts related to strategic marketing:
1. It identifies key stakeholders for healthcare organizations and pharmaceutical companies, including their interests.
2. It outlines several strategic marketing frameworks and tools, such as Porter's competitive strategies, the BCG matrix, industry life cycles, and the balanced scorecard.
3. It discusses blocks to creativity for both individuals and organizations, and reasons why new products may fail after launch.
Brand Differentiation in the Pharmaceutical Industry: Interview with: Robert Finkel, Principal & Chief Creative Officer, Kane & Finkel Healthcare Communications, a sponsor company at the marcus evans PharmaBrand Summit 2012, on differentiating brands in the highly restricted pharmaceuticals industry.
Promed is an ophthalmology focused specialty pharmaceutical company that has established a global presence in Russia, India, and other markets. It is pursuing a differentiated strategy to become a fully integrated global pharmaceutical company through organic growth and acquisitions. This includes expanding into new therapeutic areas and markets like the US through partnerships, in-licensing, and acquisitions. Promed is well positioned for global growth due to its innovation-driven culture, integrated operations, and regulatory expertise across major markets.
The differentiation pharma needs in marketing in the advanced markets, Rob Ha...A.R.J. (Rob) Halkes
What differentiation in market approach must pharma be able to do in advanced markets.
How to perform them?
What changes to business?
Rob Halkes, October 2009.
Healthscape Pharma Marketing Capability Building Program "Building Big Brands"Shailesh Rau
HealthScape is a strategic consulting and business advisory services firm set up in 2012. HealthScape provides data driven strategic insights and helps build both marketing and strategic capabilities in building big brands, product portfolios and new product launches. We aim to be the preferred and trusted partner across all dimensions of product marketing and portfolio management. We also drive high science programs besides product marketing like market shaping/disease shaping initiatives, Preceptorship Programs, CME Accredited Modules etc.
Capability Building Program:
Building Big Brands is a marketing workshop which is delivered over a period of six days, and followed by hand holding of participants over a period of 6-12 months.
Target Audience: Product Managers, Marketing Managers, Medical Affairs Managers and Market Research.
Program revolves over three key pillars which are:
A. Thorough environment scan to develop deeper understanding and value of key insights,
B. The art and science of brand positioning and
C. Conveying this value proposition in a powerful way, so as to build a solid differential over competition.
Each of these pillars is delivered through following workshop modules:
1. Importance of key customer insights
a. Fundamental understanding on insights, importance and value of market research.
b. Tools
c. Templates (A standard process for any organization to bring in a discipline)
d. Case Studies (Both from Pharma and non-pharma)
e. Simulation exercise on company’s own brand
2. Importance of Brand Positioning
a. Fundamental understanding of both science and art of developing brand positioning statement
b. Tools
c. Templates
d. Case Studies (Both from pharma and non pharma)
e. Simulation exercise on company’s own brand.
3. How to develop powerful communication/ Medico-Marketing Programs
a. Fundamental understanding of communication strategy
b. Tools
c. Templates
d. Case Studies (both from pharma and non pharma)
e. Simulation exercise on company’s own brand.
We ensure that this does not get viewed as a mere annual activity, but create a back bone of the functioning and we strongly recommend a simulation of these learnings on one of the company’s own brand.
This method of delivery of this workshop makes it most unique and valuable capability building program.
This document summarizes key concepts from a chapter on product and brand strategy from an innovation management textbook. It discusses definitions of products and brands, levels of products, market introduction of brands throughout history, the benefits of branding for buyers and sellers, and strategies for product differentiation, platforms, and portfolios. The summaries cover topics like the 6 levels of brand meaning, internal and external brand contacts, and elements of a successful product strategy.
Choice and application of strategic management methodsGints Turlajs
Gints Turlajs presented several enterprise strategy management tools including the balanced scorecard, six sigma, blue ocean strategy, BCG matrix, SWOT analysis, and Bowman's strategy clock. He provided concise descriptions of the core features and most effective applications of each tool. He then proposed an algorithm for selecting and applying these tools that involves using Deming's cycle of plan-do-check-act. He focused particularly on explaining blue ocean strategy and how to practically apply it, including using game theory and developing new demand and supply curves through creating an uncontested market space.
This document discusses several factors and concepts related to strategic marketing:
1. It identifies key stakeholders for healthcare organizations and pharmaceutical companies, including their interests.
2. It outlines several strategic marketing frameworks and tools, such as Porter's competitive strategies, the BCG matrix, industry life cycles, and the balanced scorecard.
3. It discusses blocks to creativity for both individuals and organizations, and reasons why new products may fail after launch.
Brand Differentiation in the Pharmaceutical Industry: Interview with: Robert Finkel, Principal & Chief Creative Officer, Kane & Finkel Healthcare Communications, a sponsor company at the marcus evans PharmaBrand Summit 2012, on differentiating brands in the highly restricted pharmaceuticals industry.
Promed is an ophthalmology focused specialty pharmaceutical company that has established a global presence in Russia, India, and other markets. It is pursuing a differentiated strategy to become a fully integrated global pharmaceutical company through organic growth and acquisitions. This includes expanding into new therapeutic areas and markets like the US through partnerships, in-licensing, and acquisitions. Promed is well positioned for global growth due to its innovation-driven culture, integrated operations, and regulatory expertise across major markets.
The differentiation pharma needs in marketing in the advanced markets, Rob Ha...A.R.J. (Rob) Halkes
What differentiation in market approach must pharma be able to do in advanced markets.
How to perform them?
What changes to business?
Rob Halkes, October 2009.
Healthscape Pharma Marketing Capability Building Program "Building Big Brands"Shailesh Rau
HealthScape is a strategic consulting and business advisory services firm set up in 2012. HealthScape provides data driven strategic insights and helps build both marketing and strategic capabilities in building big brands, product portfolios and new product launches. We aim to be the preferred and trusted partner across all dimensions of product marketing and portfolio management. We also drive high science programs besides product marketing like market shaping/disease shaping initiatives, Preceptorship Programs, CME Accredited Modules etc.
Capability Building Program:
Building Big Brands is a marketing workshop which is delivered over a period of six days, and followed by hand holding of participants over a period of 6-12 months.
Target Audience: Product Managers, Marketing Managers, Medical Affairs Managers and Market Research.
Program revolves over three key pillars which are:
A. Thorough environment scan to develop deeper understanding and value of key insights,
B. The art and science of brand positioning and
C. Conveying this value proposition in a powerful way, so as to build a solid differential over competition.
Each of these pillars is delivered through following workshop modules:
1. Importance of key customer insights
a. Fundamental understanding on insights, importance and value of market research.
b. Tools
c. Templates (A standard process for any organization to bring in a discipline)
d. Case Studies (Both from Pharma and non-pharma)
e. Simulation exercise on company’s own brand
2. Importance of Brand Positioning
a. Fundamental understanding of both science and art of developing brand positioning statement
b. Tools
c. Templates
d. Case Studies (Both from pharma and non pharma)
e. Simulation exercise on company’s own brand.
3. How to develop powerful communication/ Medico-Marketing Programs
a. Fundamental understanding of communication strategy
b. Tools
c. Templates
d. Case Studies (both from pharma and non pharma)
e. Simulation exercise on company’s own brand.
We ensure that this does not get viewed as a mere annual activity, but create a back bone of the functioning and we strongly recommend a simulation of these learnings on one of the company’s own brand.
This method of delivery of this workshop makes it most unique and valuable capability building program.
This document summarizes key concepts from a chapter on product and brand strategy from an innovation management textbook. It discusses definitions of products and brands, levels of products, market introduction of brands throughout history, the benefits of branding for buyers and sellers, and strategies for product differentiation, platforms, and portfolios. The summaries cover topics like the 6 levels of brand meaning, internal and external brand contacts, and elements of a successful product strategy.
Choice and application of strategic management methodsGints Turlajs
Gints Turlajs presented several enterprise strategy management tools including the balanced scorecard, six sigma, blue ocean strategy, BCG matrix, SWOT analysis, and Bowman's strategy clock. He provided concise descriptions of the core features and most effective applications of each tool. He then proposed an algorithm for selecting and applying these tools that involves using Deming's cycle of plan-do-check-act. He focused particularly on explaining blue ocean strategy and how to practically apply it, including using game theory and developing new demand and supply curves through creating an uncontested market space.
This document discusses success factors and failure points for biopharmaceutical product launches based on research with 38 companies. Key findings include:
1. Differentiation through efficacy, safety profile, and clearly defined patient population are most effective for positioning. Secondary benefits like ease-of-use can also differentiate in crowded markets.
2. Thought leader engagement, such as through advisory boards and clinical trial involvement, is important for educating physicians.
3. Educating payers on pricing, comparative effectiveness and reimbursement is also critical for market entry success.
Success Factors and Failure Points in Biopharmaceutical Product Launches: An ...Best Practices
*Oncology, Metabolic, and Cardiovascular segmentations are available. The summaries can be found under the "New Product Planning and Launch" portion of our SlideShare channel.
Success Factors and Failure Points in Metabolic Product LaunchesBest Practices, LLC
The document discusses strategies for successfully launching new metabolic products. It finds that differentiating a product based on efficacy, safety profile, and meeting an unmet medical need for a clearly defined patient population are most effective. For diabetes launches specifically, unmet need and clear patient group are the top differentiators. Engaging thought leaders through advisory boards and clinical trial involvement is also seen as highly effective. KOL engagement should span national, regional, academic and local influencers. Lack of differentiation from competitors can negatively impact payers, physicians and patient adoption.
The document provides an overview of SWOT analysis, including its history and development at Stanford Research Institute from 1960-1970. It describes the key components of a SWOT analysis - strengths, weaknesses, opportunities, and threats - and how they relate to an organization's internal and external environment. Examples are given of strengths, weaknesses, opportunities, and threats for companies like McDonald's and Nokia to illustrate how a SWOT analysis can be conducted.
This document provides an overview of key concepts in business strategy and strategic planning. It discusses frameworks for analyzing the external business environment, such as the PESTEL and Five Forces frameworks. It also covers internal organizational analysis and stakeholder analysis. Key strategic planning concepts summarized include the Ansoff Matrix, the Boston Consulting Group matrix for classifying business units, and the importance of understanding stakeholders' needs, priorities, and sources of power within an organization.
Success Factors and Failure Points in Metabolic Product Launches Report SummaryBest Practices
Biopharmaceutical companies invest large amount of resources to develop and launch new products for metabolic therapeutic areas. However, the complexity of a new metabolic product launch is compounded by the many pitfalls that are part of the market-entry landscape.
Best Practices
®, LLC undertook this research to showcase current and future risk levels for various pitfalls across critical launch fronts that can derail a new metabolic product. Pharmaceutical launch executives can use this study to better understand the potential pitfalls and stumbling blocks that they'll have to navigate as part of a new metabolic product entering the market.
Study Overview–-
This study explores the executive insights, best practices and lessons learned to avoid common pitfalls while launching a new metabolic product into market.
About the Benchmark Class -
Forty four executives from 38 leading companies including Abbott, Amgen, Baxter, Bayer, Eisai, GlaxoSmithKline, Merck, Novartis, and Roche participated in this study. Majority of the respondents were at vice president or director level.
Section 1: Study Background --
Reviews the study background, the research approach, methodology, participant demographics, the benchmark class and key findings.
Section 2: Topical chapters --
Outlines valuable insights and findings from the study that includes pitfalls & stumbling blocks, lessons learned and best practices and future changes. Pitfalls chapter reviews current and future risk levels for these metabolic launch factors: product shaping, market shaping, physician, patient, payer, internal and regulatory.
New data spotlight value of Train + Test approach to close dangerous regulatory knowledge gaps.
Expert presents 3-point plan to enhance compliance education (Slide 49 and 55)
Pharmaceutical and biotech companies realize the importance of educating the payer sector to improve the likelihood of a successful launch of their new products. As payers’ influence in the marketplace has grown, so has the importance of effective payer education tactics and strategies. This Best Practices®, LLC benchmarking study provides benchmarks around timing of payer-oriented market education and effective education tactics for payers.
This document provides a summary of a research paper on communication strategies for targeting early adopters of new products and technologies.
[1] It begins with an introduction that defines early adopters, explains their importance to brands, and outlines the objectives and research questions of the paper.
[2] The analysis section then examines early adopters as a strategic target, providing details on who they are and how they differ from mass consumers. It also explores appealing advertising approaches and the benefits early adopters provide.
[3] Several case studies of products like the iPhone, Windows Vista, and Airbus 360 are presented to illustrate campaigns that targeted early adopters.
[4] The paper concludes by emphasizing
This document discusses strategic management and strategic alternatives. It defines key terms like strategic business unit (SBU) and strategy. It describes the evolution of strategic planning and discusses portfolio restructuring, strategic options like growth, divestment, and investment. It also covers strategies for declining, mature and emerging markets, as well as competitive strategy, core competencies, competitive advantages, diversification, knowledge management, and reasons for diversifying.
This document discusses strategic management and strategic alternatives. It defines key terms like strategic business unit (SBU) and strategy. It describes the evolution of strategic planning and discusses portfolio restructuring, strategic options like growth, divestment, and investment. It also covers strategies for declining, mature and emerging markets, as well as competitive strategy, core competencies, competitive advantages, diversification, and knowledge management.
This document is a quarterly newsletter from The Sarian Group tracking the Philadelphia life sciences industry. It includes the following:
1. An article on the importance of competitive intelligence for biotech companies.
2. An article on considerations for pre-IPO recruiting and engagement of search firms.
3. A section tracking the performance of local publicly traded life sciences companies through an index and providing the top gainers and decliners year-to-date.
4. An interview with the CEO of Egalet on strategies for driving a company towards an exit through strategic sale or IPO.
This document is a quarterly newsletter from The Sarian Group tracking the Philadelphia life sciences industry. It includes the following:
1. An article on the importance of competitive intelligence for biotech companies.
2. An article on considerations for pre-IPO recruiting and engagement of search firms.
3. A section showing the performance of The Sarian Group Index which tracks publicly traded life sciences companies in the region against benchmarks. It lists top gainers and decliners year-to-date.
4. An interview with the CEO of Egalet on strategies for driving a company towards a strategic sale or IPO.
This document discusses various strategic management concepts including strategic business units, corporate strategy, strategic planning, portfolio analysis, competitive strategies, diversification, and knowledge management. It provides definitions and explanations of these key terms and discusses how companies can analyze their business portfolio, choose strategic options, and build competitive advantages.
This document discusses various strategic management concepts including strategic business units, corporate strategy, strategic planning, portfolio analysis, competitive strategy, core competencies, competitive advantages, diversification, and knowledge management. It provides definitions and explanations of these key terms and discusses how companies can analyze their business portfolios, choose strategic options, and develop competitive advantages.
This document discusses several marketing gurus and the concepts they developed, including Igor Ansoff and his product-market growth matrix and Ansoff's matrix, Theodore Levitt and his product life cycle concept and management, and Albert Humphrey and his SWOT analysis technique. It also covers the BCG growth-share matrix developed by Bruce Henderson of Boston Consulting Group. The gurus and concepts discussed provide analytical tools for areas like brand marketing, product management, strategic management, and portfolio analysis.
Regulatory affairs professionals ensure public health by controlling the safety and efficacy of products. They keep track of changing legislation and advise their company on legal and scientific requirements. They collect and evaluate scientific data, present registration documents to regulatory agencies, and obtain marketing authorization for products. A good regulatory affairs professional helps maximize resources and serves as the first point of contact between a company and government authorities.
Pfizer strategy for internationalizationAamir chouhan
This document provides an overview of Pfizer, a global pharmaceutical company. It discusses Pfizer's vision, mission, strategic moves, organizational structure, and key financial metrics. Pfizer discovers, develops, and markets prescription medicines for humans and animals. It has grown through acquisitions and partnerships, and restructured in 2014 to focus on innovative pharmaceuticals, vaccines, and consumer healthcare. Pfizer faces challenges from patent expirations and increasing costs of drug development.
What strategies should be employed to win in Biosimilars?Santhosh R
What are the key strategies to win in biosimilars market? What should be your plan for payers, physicians, and launch? What should be the focus for pharmaceutical / biosimilar companies?
Key Takeaways -
- There is a need for a holistic approach to succeed in this market environment
- Many biologics are administered by physicians; therefore, more emphasis will have to be directed at the physicians than was the case with small-molecule generics
- Carefully constructed incentive from public and private payers / PBMs could boost biosimilar utilization significantly
- Companies need to instill confidence & awareness in patients just like they do with other stakeholders
- Launch biosimilars in emerging markets before developed markets to develop strong post-marketing data
- Manufacturing biosimilars requires scientific expertise and experience
- Success Checklist
Discover timeless style with the 2022 Vintage Roman Numerals Men's Ring. Crafted from premium stainless steel, this 6mm wide ring embodies elegance and durability. Perfect as a gift, it seamlessly blends classic Roman numeral detailing with modern sophistication, making it an ideal accessory for any occasion.
https://rb.gy/usj1a2
Best practices for project execution and deliveryCLIVE MINCHIN
A select set of project management best practices to keep your project on-track, on-cost and aligned to scope. Many firms have don't have the necessary skills, diligence, methods and oversight of their projects; this leads to slippage, higher costs and longer timeframes. Often firms have a history of projects that simply failed to move the needle. These best practices will help your firm avoid these pitfalls but they require fortitude to apply.
This document discusses success factors and failure points for biopharmaceutical product launches based on research with 38 companies. Key findings include:
1. Differentiation through efficacy, safety profile, and clearly defined patient population are most effective for positioning. Secondary benefits like ease-of-use can also differentiate in crowded markets.
2. Thought leader engagement, such as through advisory boards and clinical trial involvement, is important for educating physicians.
3. Educating payers on pricing, comparative effectiveness and reimbursement is also critical for market entry success.
Success Factors and Failure Points in Biopharmaceutical Product Launches: An ...Best Practices
*Oncology, Metabolic, and Cardiovascular segmentations are available. The summaries can be found under the "New Product Planning and Launch" portion of our SlideShare channel.
Success Factors and Failure Points in Metabolic Product LaunchesBest Practices, LLC
The document discusses strategies for successfully launching new metabolic products. It finds that differentiating a product based on efficacy, safety profile, and meeting an unmet medical need for a clearly defined patient population are most effective. For diabetes launches specifically, unmet need and clear patient group are the top differentiators. Engaging thought leaders through advisory boards and clinical trial involvement is also seen as highly effective. KOL engagement should span national, regional, academic and local influencers. Lack of differentiation from competitors can negatively impact payers, physicians and patient adoption.
The document provides an overview of SWOT analysis, including its history and development at Stanford Research Institute from 1960-1970. It describes the key components of a SWOT analysis - strengths, weaknesses, opportunities, and threats - and how they relate to an organization's internal and external environment. Examples are given of strengths, weaknesses, opportunities, and threats for companies like McDonald's and Nokia to illustrate how a SWOT analysis can be conducted.
This document provides an overview of key concepts in business strategy and strategic planning. It discusses frameworks for analyzing the external business environment, such as the PESTEL and Five Forces frameworks. It also covers internal organizational analysis and stakeholder analysis. Key strategic planning concepts summarized include the Ansoff Matrix, the Boston Consulting Group matrix for classifying business units, and the importance of understanding stakeholders' needs, priorities, and sources of power within an organization.
Success Factors and Failure Points in Metabolic Product Launches Report SummaryBest Practices
Biopharmaceutical companies invest large amount of resources to develop and launch new products for metabolic therapeutic areas. However, the complexity of a new metabolic product launch is compounded by the many pitfalls that are part of the market-entry landscape.
Best Practices
®, LLC undertook this research to showcase current and future risk levels for various pitfalls across critical launch fronts that can derail a new metabolic product. Pharmaceutical launch executives can use this study to better understand the potential pitfalls and stumbling blocks that they'll have to navigate as part of a new metabolic product entering the market.
Study Overview–-
This study explores the executive insights, best practices and lessons learned to avoid common pitfalls while launching a new metabolic product into market.
About the Benchmark Class -
Forty four executives from 38 leading companies including Abbott, Amgen, Baxter, Bayer, Eisai, GlaxoSmithKline, Merck, Novartis, and Roche participated in this study. Majority of the respondents were at vice president or director level.
Section 1: Study Background --
Reviews the study background, the research approach, methodology, participant demographics, the benchmark class and key findings.
Section 2: Topical chapters --
Outlines valuable insights and findings from the study that includes pitfalls & stumbling blocks, lessons learned and best practices and future changes. Pitfalls chapter reviews current and future risk levels for these metabolic launch factors: product shaping, market shaping, physician, patient, payer, internal and regulatory.
New data spotlight value of Train + Test approach to close dangerous regulatory knowledge gaps.
Expert presents 3-point plan to enhance compliance education (Slide 49 and 55)
Pharmaceutical and biotech companies realize the importance of educating the payer sector to improve the likelihood of a successful launch of their new products. As payers’ influence in the marketplace has grown, so has the importance of effective payer education tactics and strategies. This Best Practices®, LLC benchmarking study provides benchmarks around timing of payer-oriented market education and effective education tactics for payers.
This document provides a summary of a research paper on communication strategies for targeting early adopters of new products and technologies.
[1] It begins with an introduction that defines early adopters, explains their importance to brands, and outlines the objectives and research questions of the paper.
[2] The analysis section then examines early adopters as a strategic target, providing details on who they are and how they differ from mass consumers. It also explores appealing advertising approaches and the benefits early adopters provide.
[3] Several case studies of products like the iPhone, Windows Vista, and Airbus 360 are presented to illustrate campaigns that targeted early adopters.
[4] The paper concludes by emphasizing
This document discusses strategic management and strategic alternatives. It defines key terms like strategic business unit (SBU) and strategy. It describes the evolution of strategic planning and discusses portfolio restructuring, strategic options like growth, divestment, and investment. It also covers strategies for declining, mature and emerging markets, as well as competitive strategy, core competencies, competitive advantages, diversification, knowledge management, and reasons for diversifying.
This document discusses strategic management and strategic alternatives. It defines key terms like strategic business unit (SBU) and strategy. It describes the evolution of strategic planning and discusses portfolio restructuring, strategic options like growth, divestment, and investment. It also covers strategies for declining, mature and emerging markets, as well as competitive strategy, core competencies, competitive advantages, diversification, and knowledge management.
This document is a quarterly newsletter from The Sarian Group tracking the Philadelphia life sciences industry. It includes the following:
1. An article on the importance of competitive intelligence for biotech companies.
2. An article on considerations for pre-IPO recruiting and engagement of search firms.
3. A section tracking the performance of local publicly traded life sciences companies through an index and providing the top gainers and decliners year-to-date.
4. An interview with the CEO of Egalet on strategies for driving a company towards an exit through strategic sale or IPO.
This document is a quarterly newsletter from The Sarian Group tracking the Philadelphia life sciences industry. It includes the following:
1. An article on the importance of competitive intelligence for biotech companies.
2. An article on considerations for pre-IPO recruiting and engagement of search firms.
3. A section showing the performance of The Sarian Group Index which tracks publicly traded life sciences companies in the region against benchmarks. It lists top gainers and decliners year-to-date.
4. An interview with the CEO of Egalet on strategies for driving a company towards a strategic sale or IPO.
This document discusses various strategic management concepts including strategic business units, corporate strategy, strategic planning, portfolio analysis, competitive strategies, diversification, and knowledge management. It provides definitions and explanations of these key terms and discusses how companies can analyze their business portfolio, choose strategic options, and build competitive advantages.
This document discusses various strategic management concepts including strategic business units, corporate strategy, strategic planning, portfolio analysis, competitive strategy, core competencies, competitive advantages, diversification, and knowledge management. It provides definitions and explanations of these key terms and discusses how companies can analyze their business portfolios, choose strategic options, and develop competitive advantages.
This document discusses several marketing gurus and the concepts they developed, including Igor Ansoff and his product-market growth matrix and Ansoff's matrix, Theodore Levitt and his product life cycle concept and management, and Albert Humphrey and his SWOT analysis technique. It also covers the BCG growth-share matrix developed by Bruce Henderson of Boston Consulting Group. The gurus and concepts discussed provide analytical tools for areas like brand marketing, product management, strategic management, and portfolio analysis.
Regulatory affairs professionals ensure public health by controlling the safety and efficacy of products. They keep track of changing legislation and advise their company on legal and scientific requirements. They collect and evaluate scientific data, present registration documents to regulatory agencies, and obtain marketing authorization for products. A good regulatory affairs professional helps maximize resources and serves as the first point of contact between a company and government authorities.
Pfizer strategy for internationalizationAamir chouhan
This document provides an overview of Pfizer, a global pharmaceutical company. It discusses Pfizer's vision, mission, strategic moves, organizational structure, and key financial metrics. Pfizer discovers, develops, and markets prescription medicines for humans and animals. It has grown through acquisitions and partnerships, and restructured in 2014 to focus on innovative pharmaceuticals, vaccines, and consumer healthcare. Pfizer faces challenges from patent expirations and increasing costs of drug development.
What strategies should be employed to win in Biosimilars?Santhosh R
What are the key strategies to win in biosimilars market? What should be your plan for payers, physicians, and launch? What should be the focus for pharmaceutical / biosimilar companies?
Key Takeaways -
- There is a need for a holistic approach to succeed in this market environment
- Many biologics are administered by physicians; therefore, more emphasis will have to be directed at the physicians than was the case with small-molecule generics
- Carefully constructed incentive from public and private payers / PBMs could boost biosimilar utilization significantly
- Companies need to instill confidence & awareness in patients just like they do with other stakeholders
- Launch biosimilars in emerging markets before developed markets to develop strong post-marketing data
- Manufacturing biosimilars requires scientific expertise and experience
- Success Checklist
Discover timeless style with the 2022 Vintage Roman Numerals Men's Ring. Crafted from premium stainless steel, this 6mm wide ring embodies elegance and durability. Perfect as a gift, it seamlessly blends classic Roman numeral detailing with modern sophistication, making it an ideal accessory for any occasion.
https://rb.gy/usj1a2
Best practices for project execution and deliveryCLIVE MINCHIN
A select set of project management best practices to keep your project on-track, on-cost and aligned to scope. Many firms have don't have the necessary skills, diligence, methods and oversight of their projects; this leads to slippage, higher costs and longer timeframes. Often firms have a history of projects that simply failed to move the needle. These best practices will help your firm avoid these pitfalls but they require fortitude to apply.
IMPACT Silver is a pure silver zinc producer with over $260 million in revenue since 2008 and a large 100% owned 210km Mexico land package - 2024 catalysts includes new 14% grade zinc Plomosas mine and 20,000m of fully funded exploration drilling.
Easily Verify Compliance and Security with Binance KYCAny kyc Account
Use our simple KYC verification guide to make sure your Binance account is safe and compliant. Discover the fundamentals, appreciate the significance of KYC, and trade on one of the biggest cryptocurrency exchanges with confidence.
The Genesis of BriansClub.cm Famous Dark WEb PlatformSabaaSudozai
BriansClub.cm, a famous platform on the dark web, has become one of the most infamous carding marketplaces, specializing in the sale of stolen credit card data.
How to Implement a Strategy: Transform Your Strategy with BSC Designer's Comp...Aleksey Savkin
The Strategy Implementation System offers a structured approach to translating stakeholder needs into actionable strategies using high-level and low-level scorecards. It involves stakeholder analysis, strategy decomposition, adoption of strategic frameworks like Balanced Scorecard or OKR, and alignment of goals, initiatives, and KPIs.
Key Components:
- Stakeholder Analysis
- Strategy Decomposition
- Adoption of Business Frameworks
- Goal Setting
- Initiatives and Action Plans
- KPIs and Performance Metrics
- Learning and Adaptation
- Alignment and Cascading of Scorecards
Benefits:
- Systematic strategy formulation and execution.
- Framework flexibility and automation.
- Enhanced alignment and strategic focus across the organization.
Part 2 Deep Dive: Navigating the 2024 Slowdownjeffkluth1
Introduction
The global retail industry has weathered numerous storms, with the financial crisis of 2008 serving as a poignant reminder of the sector's resilience and adaptability. However, as we navigate the complex landscape of 2024, retailers face a unique set of challenges that demand innovative strategies and a fundamental shift in mindset. This white paper contrasts the impact of the 2008 recession on the retail sector with the current headwinds retailers are grappling with, while offering a comprehensive roadmap for success in this new paradigm.
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.AnnySerafinaLove
This letter, written by Kellen Harkins, Course Director at Full Sail University, commends Anny Love's exemplary performance in the Video Sharing Platforms class. It highlights her dedication, willingness to challenge herself, and exceptional skills in production, editing, and marketing across various video platforms like YouTube, TikTok, and Instagram.
How MJ Global Leads the Packaging Industry.pdfMJ Global
MJ Global's success in staying ahead of the curve in the packaging industry is a testament to its dedication to innovation, sustainability, and customer-centricity. By embracing technological advancements, leading in eco-friendly solutions, collaborating with industry leaders, and adapting to evolving consumer preferences, MJ Global continues to set new standards in the packaging sector.
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Final ank Satta Matka Dpbos Final ank Satta Matta Matka 143 Kalyan Matka Guessing Final Matka Final ank Today Matka 420 Satta Batta Satta 143 Kalyan Chart Main Bazar Chart vip Matka Guessing Dpboss 143 Guessing Kalyan night
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdfthesiliconleaders
In the recent edition, The 10 Most Influential Leaders Guiding Corporate Evolution, 2024, The Silicon Leaders magazine gladly features Dejan Štancer, President of the Global Chamber of Business Leaders (GCBL), along with other leaders.
Brian Fitzsimmons on the Business Strategy and Content Flywheel of Barstool S...Neil Horowitz
On episode 272 of the Digital and Social Media Sports Podcast, Neil chatted with Brian Fitzsimmons, Director of Licensing and Business Development for Barstool Sports.
What follows is a collection of snippets from the podcast. To hear the full interview and more, check out the podcast on all podcast platforms and at www.dsmsports.net
Digital Marketing with a Focus on Sustainabilitysssourabhsharma
Digital Marketing best practices including influencer marketing, content creators, and omnichannel marketing for Sustainable Brands at the Sustainable Cosmetics Summit 2024 in New York
The APCO Geopolitical Radar - Q3 2024 The Global Operating Environment for Bu...APCO
The Radar reflects input from APCO’s teams located around the world. It distils a host of interconnected events and trends into insights to inform operational and strategic decisions. Issues covered in this edition include:
4. Exhibit 1.1 Selected stakeholders Interests for
an NHS organization
Stakeholder Interests
Staff
Provision of quality health care
Self development and promotion prospects
Current Job Satisfaction
Receive excellent care and attention
Work in a safe and good quality environment
Enhance health prospects and life expectancy
Patients
Advice on how best to recover from treatment and avoid future health problems
Unions
Access to information
Responsibility to members to ensure fair working practices, safe environment
Support from medical staff
Support and advise members in all areas of employment rights, i.e. Equal Opportunities, Discrimination,
Racial Incidents
Government
Recruitment of new members
Quality Standards
Legal requirements/Health and Safety/Equal Opps/Pay and Conditions
Press
Financial Management, high achievementbeing used and managed effectively
Praise and publicity for ensure resources
Adverse publicity – making the facts known
Prospective Patients
Challenging use of finances and pleasant environment
Excellent treatment in a caring
Access to information
Choices
5. Exhibit 1.2 Stakeholders for a pharmaceutical company
Stakeholders Interests
General public Safe, reliable, tested drugs
Legal/ courts Tested drugs which do not result in serious side effects
for the users.
Government Reasonably priced drugs which have been shown to be
effective in use.
Media Stories showing either the benefits of drugs or very
harmful side-effects of drugs which have not been
properly tested.
Scientific Community Details of development and testing of new drugs.
Shareholders Return on investment and shareholder value created.
Suppliers Steady and secure demand for the products and services it
supplies.
Financial institutions A sound developing and following sound marketing and
corporate strategies which will produce guaranteed
returns from lending and investment.
Rank and file employees Secure and interesting employment with good future
prospects.
Competitors New developments that lead to competitive advantage.
Consumers Safe and effective treatments.
Management Control and influence over what happens in the firm.
13. ADL Matrix
Industry life
cycle stage
Competitive Embryonic Growth Mature Aging
Position
Dominant Hold position and Hold position and Hold position and Hold position
seek to maximize share expand with
share industry
Strong Attempt to Attempt to Hold position and Hold position or
improve position improve position expand with harvest
and maximize and be selective in industry
share attempts to
improve share
Favourable Selective attempts Attempt to Find niche and Harvest or phased out
to improve improve position attempt to guard withdrawal
position and be selective in it.
attempts to
improve share
Tenable Selectively push Find niche and Find niche and Phased out
for position attempt to guard it hang on or phased withdrawal or
out withdrawal
abandon
Weak Improve or get out Turnaround or Turn around or Abandon
abandon phased out
withdrawal
17. EXHIBIT 3.5 FORD MODEL ‘T’—THE MINDSET OF HENRY
FORD
Henry Ford’s model ‘T’ remained unchanged for years while General
Motors (Chevrolet) was making changes often using new technology.
Henry Ford said: ‘We’ll give the customer any colour he wants as long
as it is black.’ It was an arrogant statement by an arrogant man who had
been on top so long he thought nothing could dislodge him from the
number one position.
In the late 1920s Ford nearly went out of business as a result of this
myopic approach. General Motors (Chevrolet) took over as number one
in the US and Ford did not catch up until the late 1980s.
18. Blocks to Individual Creativity
Strategic blocks: ‘one right answer approaches’, inflexibility in thinking. These
affect the approach taken to solve problems. They include the tendency to rely
heavily on past experience or particular techniques without challenging their
appropriateness; focusing on a narrow range of options for either problem
definition or problem solving; and adapting an over-ly serious approach to
problems which prevents the emergence of a playful, imaginative and humorous
climate.
V alue blocks: ‘over-generalized rigidity influenced by personal values’.
These occur when personal beliefs and values restrict the range of ideas
contemplated. Values co-exist and failure to reconcile them contributes to
difficult personal and organizational dilemmas.
Perceptual blocks: ‘over-narrow focus of attention and interest’. These arise
from a lack of sensory awareness at a physical level and therefore contribute to a
lack of awareness of implications of situations.
Self-image blocks: ‘poor effectiveness through fear of failure, timidity in
expressing ideas, etc.’. These reduce effectiveness in advancing ideas assertively.
They arise from a lack of self confidence in the value of one’s own ideas.
Individuals may be reluctant to seek help and talk about personal feelings.This
19. EXHIBIT 3.6 BLOCKS TO CREATIVITY IN ORGANIZATIONS
People and organizations tend to fall into a variety of traps when
trying to become more innovative.
1 Identifying the wrong problem
2 Judging ideas too quickly
3 Stopping with the first good idea
4 Failing to get the support of key personnel in the organization
5 Failing to challenge assumptions
54. International Market Entry Methods
• Indirect export
• Direct export:
• A domestic-based export department or division
• An overseas sales branch or subsidiary
• Travelling export sales representatives
• Foreign-based distributors or agents
• Licensing
• Joint ventures
• Direct Investment
55. E XHIBIT 12.2 WHA T IS A NE W PRODUC T?
New to the world products: inventions— in-line skates,
Polaroid cam era, etc.
New category entries: P& G’s first sham poo, Ford ’s first M ini
Additions to product lines: Tid e liquid d etergent Product
improvements: current prod ucts m ad e better Repositionings:
Arm & H am m er’s baking sod a repositioned several tim es as
d rain
d eod orant, refrigerator d eod orant, etc
.
56. Reasons for product failure
• products lack useful/meaningful uniqueness
• planning is poor during the introduction phase
• the introduction is badly timed, e.g. before the market is ready for
the product
• key important points are sometimes overlooked in the enthusiasm to
go ahead
• poor marketing and failure after launch
• the top management in the organization does not provide adequate
support for the product
• company politics, e.g. between various brand managers
• unforeseen high product costs.
59. E XHIBIT 12.9 C ONC E PT TE STING
Uniqueness of the concept
Believability of the concept
Importance of the problem being addressed
Extent to which the concept is interesting
Extent to which it is realistic, practical, useful
Extent to which it solves a problem or meets a need
How much they like the concept
How likely they would be to buy the product
Their reactions to the proposed price
What problems they see in using the product